5:10 PM
 | 
Feb 23, 2010
 |  BC Extra  |  Clinical News

Amylin, Takeda discontinue davalintide

Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) discontinued development of davalintide in favor of their other obesity compound in Phase II testing, pramlintide/metreleptin. A Phase II trial to treat obesity...

Read the full 156 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >